 Jordan Karlitz
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 35 | 2026 | 866 | 8.200 |
Why?
| | Early Detection of Cancer | 25 | 2026 | 485 | 6.000 |
Why?
| | Colonoscopy | 16 | 2026 | 263 | 3.590 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2021 | 41 | 2.700 |
Why?
| | Feces | 11 | 2026 | 495 | 2.440 |
Why?
| | Adenocarcinoma | 7 | 2024 | 925 | 2.160 |
Why?
| | Carcinoid Tumor | 3 | 2022 | 21 | 2.070 |
Why?
| | Patient Compliance | 11 | 2026 | 587 | 2.070 |
Why?
| | Colonic Neoplasms | 5 | 2022 | 257 | 1.110 |
Why?
| | Mass Screening | 9 | 2026 | 1360 | 1.040 |
Why?
| | Telemedicine | 3 | 2021 | 961 | 1.020 |
Why?
| | Occult Blood | 6 | 2026 | 40 | 0.970 |
Why?
| | Genetic Testing | 2 | 2018 | 480 | 0.800 |
Why?
| | DNA | 2 | 2026 | 1435 | 0.750 |
Why?
| | Appendiceal Neoplasms | 1 | 2022 | 28 | 0.740 |
Why?
| | SEER Program | 7 | 2022 | 229 | 0.710 |
Why?
| | Incidence | 9 | 2024 | 2923 | 0.710 |
Why?
| | Immunohistochemistry | 5 | 2021 | 1716 | 0.680 |
Why?
| | United States | 22 | 2026 | 16098 | 0.680 |
Why?
| | Adenoma | 2 | 2021 | 218 | 0.670 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 69 | 0.620 |
Why?
| | Microsatellite Instability | 2 | 2018 | 55 | 0.570 |
Why?
| | Colonic Polyps | 1 | 2020 | 87 | 0.560 |
Why?
| | Health Status Disparities | 2 | 2020 | 321 | 0.540 |
Why?
| | Middle Aged | 26 | 2026 | 36215 | 0.530 |
Why?
| | Humans | 50 | 2026 | 145474 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.520 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1371 | 0.500 |
Why?
| | Age of Onset | 5 | 2022 | 555 | 0.480 |
Why?
| | Colectomy | 2 | 2015 | 106 | 0.470 |
Why?
| | DNA, Neoplasm | 2 | 2026 | 158 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.440 |
Why?
| | Family | 1 | 2020 | 682 | 0.440 |
Why?
| | Male | 27 | 2026 | 72842 | 0.410 |
Why?
| | Rectal Neoplasms | 3 | 2021 | 159 | 0.400 |
Why?
| | Age Factors | 6 | 2022 | 3342 | 0.400 |
Why?
| | Colorectal Surgery | 1 | 2013 | 30 | 0.400 |
Why?
| | Follow-Up Studies | 7 | 2026 | 5423 | 0.390 |
Why?
| | Retrospective Studies | 12 | 2026 | 17291 | 0.380 |
Why?
| | Female | 27 | 2026 | 78844 | 0.360 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.350 |
Why?
| | Immunocompetence | 1 | 2010 | 46 | 0.330 |
Why?
| | Aged | 16 | 2026 | 26153 | 0.320 |
Why?
| | Medicare | 4 | 2026 | 903 | 0.320 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 176 | 0.310 |
Why?
| | Herpesvirus 4, Human | 1 | 2010 | 172 | 0.300 |
Why?
| | Adult | 17 | 2022 | 40777 | 0.290 |
Why?
| | Louisiana | 2 | 2021 | 31 | 0.280 |
Why?
| | Risk Assessment | 4 | 2022 | 3747 | 0.280 |
Why?
| | Colitis | 1 | 2010 | 280 | 0.260 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5904 | 0.260 |
Why?
| | Carcinoma | 2 | 2021 | 225 | 0.250 |
Why?
| | Immunochemistry | 1 | 2026 | 12 | 0.240 |
Why?
| | Uterine Diseases | 1 | 2006 | 18 | 0.240 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 254 | 0.240 |
Why?
| | Colonic Diseases | 1 | 2006 | 37 | 0.240 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2010 | 364 | 0.230 |
Why?
| | Endometriosis | 1 | 2006 | 58 | 0.230 |
Why?
| | Cost Sharing | 1 | 2025 | 20 | 0.230 |
Why?
| | Risk Factors | 6 | 2022 | 10885 | 0.220 |
Why?
| | Neoplasm Staging | 4 | 2022 | 1471 | 0.210 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1101 | 0.200 |
Why?
| | Appendectomy | 1 | 2022 | 90 | 0.180 |
Why?
| | MutL Protein Homolog 1 | 1 | 2021 | 11 | 0.180 |
Why?
| | Cost-Benefit Analysis | 2 | 2021 | 639 | 0.170 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2021 | 20 | 0.170 |
Why?
| | Rural Population | 2 | 2018 | 659 | 0.170 |
Why?
| | DNA Mismatch Repair | 1 | 2021 | 53 | 0.170 |
Why?
| | Forecasting | 2 | 2020 | 390 | 0.160 |
Why?
| | Clinical Competence | 1 | 2009 | 1243 | 0.160 |
Why?
| | Mutation, Missense | 1 | 2021 | 335 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2016 | 1508 | 0.150 |
Why?
| | Pathologists | 1 | 2018 | 19 | 0.140 |
Why?
| | Gastroenterologists | 1 | 2018 | 21 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2025 | 946 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2014 | 503 | 0.130 |
Why?
| | Insurance, Health | 1 | 2020 | 310 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2019 | 223 | 0.130 |
Why?
| | Medicaid | 1 | 2021 | 467 | 0.130 |
Why?
| | Organizational Objectives | 1 | 2017 | 67 | 0.130 |
Why?
| | Physician's Role | 1 | 2018 | 223 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 407 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2021 | 1111 | 0.120 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2016 | 47 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 425 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 588 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 58 | 0.100 |
Why?
| | Preoperative Period | 1 | 2015 | 149 | 0.100 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 102 | 0.100 |
Why?
| | Preoperative Care | 1 | 2016 | 380 | 0.100 |
Why?
| | Societies, Medical | 1 | 2017 | 899 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2010 | 237 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1963 | 0.090 |
Why?
| | Urban Population | 1 | 2015 | 493 | 0.090 |
Why?
| | Jejunal Diseases | 1 | 2010 | 7 | 0.080 |
Why?
| | Choristoma | 1 | 2010 | 20 | 0.080 |
Why?
| | Quality Improvement | 1 | 2018 | 1295 | 0.080 |
Why?
| | Ribavirin | 1 | 2010 | 81 | 0.080 |
Why?
| | Abdominal Pain | 2 | 2010 | 149 | 0.070 |
Why?
| | Veterans | 1 | 2021 | 1635 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 193 | 0.070 |
Why?
| | Young Adult | 3 | 2020 | 14218 | 0.070 |
Why?
| | Pancreas | 1 | 2010 | 341 | 0.070 |
Why?
| | Prevalence | 1 | 2015 | 2865 | 0.070 |
Why?
| | Hepatitis C | 1 | 2010 | 256 | 0.060 |
Why?
| | Alabama | 1 | 2026 | 32 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2016 | 1329 | 0.060 |
Why?
| | United States Department of Defense | 1 | 2026 | 24 | 0.060 |
Why?
| | Hospitals, General | 1 | 2026 | 25 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2021 | 1327 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2006 | 185 | 0.060 |
Why?
| | Israel | 1 | 2025 | 46 | 0.060 |
Why?
| | Ovariectomy | 1 | 2006 | 166 | 0.060 |
Why?
| | Registries | 1 | 2014 | 2406 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6066 | 0.060 |
Why?
| | Massachusetts | 1 | 2026 | 180 | 0.060 |
Why?
| | Hysterectomy | 1 | 2006 | 138 | 0.060 |
Why?
| | Vasculitis | 1 | 2005 | 69 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2010 | 649 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8333 | 0.050 |
Why?
| | Brain Diseases | 1 | 2005 | 155 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2010 | 769 | 0.050 |
Why?
| | Time Factors | 1 | 2015 | 7123 | 0.050 |
Why?
| | California | 1 | 2025 | 471 | 0.050 |
Why?
| | Celiac Disease | 1 | 2005 | 311 | 0.040 |
Why?
| | Language | 1 | 2025 | 323 | 0.040 |
Why?
| | North America | 1 | 2022 | 302 | 0.040 |
Why?
| | Europe | 1 | 2022 | 418 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 423 | 0.040 |
Why?
| | Colonography, Computed Tomographic | 1 | 2018 | 8 | 0.040 |
Why?
| | Disease Progression | 1 | 2006 | 2864 | 0.030 |
Why?
| | Military Personnel | 1 | 2026 | 737 | 0.030 |
Why?
| | Mutation | 2 | 2017 | 4075 | 0.030 |
Why?
| | Carcinoembryonic Antigen | 1 | 2014 | 40 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1374 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2378 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2105 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4316 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2006 | 11772 | 0.020 |
Why?
| | Urban Health | 1 | 2010 | 96 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1044 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1368 | 0.020 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2005 | 8 | 0.010 |
Why?
| | CD2 Antigens | 1 | 2005 | 7 | 0.010 |
Why?
| | Complement C4b | 1 | 2005 | 9 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2017 | 6447 | 0.010 |
Why?
| | Complement C1q | 1 | 2005 | 32 | 0.010 |
Why?
| | CD3 Complex | 1 | 2005 | 112 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2005 | 305 | 0.010 |
Why?
| | Complement C3 | 1 | 2005 | 187 | 0.010 |
Why?
| | Cohort Studies | 1 | 2014 | 6013 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10077 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 1041 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11853 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2005 | 693 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 22529 | 0.010 |
Why?
| | Child | 1 | 2017 | 22707 | 0.010 |
Why?
|
|
Karlitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|